Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University Hospital, Bordeaux
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05210413CT.gov Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults | — | Active Not Recruiting | — | — | — |
NCT01430572CT.gov Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | — | Completed | — | — | — |
NCT01454804CT.gov Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT01636908CT.gov Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | — | Completed | — | — | — |
NCT01235962CT.gov A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) | — | Completed | — | — | — |
NCT01205230CT.gov VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK | — | Completed | — | — | — |
NCT00561795CT.gov Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pazopanib (this asset) | University Hospital, Bordeaux | Approved | BB · 65 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Pazopanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Ovarian Neoplasm | — | P2 | BB · 71 |
| Non-Small Cell Lung Carcinoma | — | P2/3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pazopanib in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pazopanib-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →